AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 0.16 |
Market Cap | 6.55M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -1.1 |
PE Ratio (ttm) | -0.15 |
Forward PE | n/a |
Analyst | Buy |
Ask | 0.17 |
Volume | 618,497 |
Avg. Volume (20D) | 2,875,839 |
Open | 0.18 |
Previous Close | 0.17 |
Day's Range | 0.15 - 0.18 |
52-Week Range | 0.13 - 1.31 |
Beta | undefined |
About VIRX
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket trial for the treatment of various relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as we...
Analyst Forecast
According to 4 analyst ratings, the average rating for VIRX stock is "Buy." The 12-month stock price forecast is $3, which is an increase of 1719.28% from the latest price.